Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant.
about
Delivery of oligonucleotides with lipid nanoparticlesAdjuvant activity of CpG oligodeoxynucleotidesThe cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies.New insights for development of a safe and protective RSV vaccineTLR-based immune adjuvants.Mammalian Cell-Derived Respiratory Syncytial Virus-Like Particles Protect the Lower as well as the Upper Respiratory TractMolecular adjuvants for mucosal immunity.Use of CpG oligodeoxynucleotides as immune adjuvants.CpG DNA: immunomodulation and remodelling of the asthmatic airway.Acute and Chronic Airway Disease After Human Respiratory Syncytial Virus Infection in Cotton Rats (Sigmodon hispidus)Respiratory syncytial virus and innate immunity: a complex interplay of exploitation and subversion.Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses.TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity.Delta inulin-derived adjuvants that elicit Th1 phenotype following vaccination reduces respiratory syncytial virus lung titers without a reduction in lung immunopathology.A recombinant anchorless respiratory syncytial virus (RSV) fusion (F) protein/monophosphoryl lipid A (MPL) vaccine protects against RSV-induced replication and lung pathology.All-Atom MD Predicts Magnesium-Induced Hairpin in Chemically Perturbed RNA Analog of F10 Therapeutic.CpG in Combination with an Inhibitor of Notch Signaling Suppresses Formalin-Inactivated Respiratory Syncytial Virus-Enhanced Airway Hyperresponsiveness and Inflammation by Inhibiting Th17 Memory Responses and Promoting Tissue-Resident Memory Cells iSoluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles.Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections.Human metapneumovirus: enhanced pulmonary disease in cotton rats immunized with formalin-inactivated virus vaccine and challenged.Induction of type I interferons and interferon-inducible Mx genes during respiratory syncytial virus infection and reinfection in cotton rats.Distinct Effects of Monophosphoryl Lipid A, Oligodeoxynucleotide CpG, and Combination Adjuvants on Modulating Innate and Adaptive Immune Responses to Influenza Vaccination.Induction and Subversion of Human Protective Immunity: Contrasting Influenza and Respiratory Syncytial Virus.
P2860
Q27024646-260F07BB-9E27-4A88-A74C-B3506AC61494Q28250104-044694E2-404E-4D02-BE26-6B5F7FB4E45EQ34142834-A88F9DB4-FD08-46E5-9B94-AB32AE5A5F01Q34249859-34D6A6DC-4BEE-4C0E-85BE-64CECED26669Q34400322-8D6AD373-8BF8-4026-B480-AC504229E17FQ35690781-04EC07A1-0B88-460F-8A5F-2120E2EDF2B2Q35826381-7FF55CDA-4423-4696-8309-34EB17DBC3F2Q35826404-A8597FA2-D132-4CA5-ACB3-53BD7740B1DEQ35873799-9AB72C9B-BD17-4D44-B690-928826489172Q35996472-29A6ED76-5973-49C1-9DF3-FD75742EF862Q36530226-9B6EBA39-5857-4196-A661-F86A3506869EQ37069783-21FDF936-C64A-48C6-8507-801AF2944873Q37188620-E47A4CD0-002B-4A45-B4AD-54C4FCA33990Q37197103-106E6117-AD25-48DD-B38E-7B1BB1BE6413Q37627348-F9CF30AD-D627-44AA-BD65-B1F94149327CQ38660825-1648BEE4-6DC4-4DAC-AE21-FA3F5BEFFCFBQ38919640-57235454-48BA-43B1-A164-A0E665D9D110Q40065136-3185FBAB-AF00-4D2C-BBD3-98FF40B4C556Q41055844-D0BF666B-456B-4C54-9A4C-DAE74B504CBBQ42428474-972BB9F7-40EA-4C84-BF26-BD8469DA24E6Q42551081-803E9E70-BB9E-4C1A-8AF3-694049AAFF92Q47143691-EF1B368B-4527-476D-9071-8DA3AAC51AA7Q52649839-9D294210-2A54-4C03-82F9-45DC9D005D01
P2860
Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant.
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Immunoprotective activity and ...... oligodeoxynucleotide adjuvant.
@ast
Immunoprotective activity and ...... oligodeoxynucleotide adjuvant.
@en
Immunoprotective activity and ...... oligodeoxynucleotide adjuvant.
@nl
type
label
Immunoprotective activity and ...... oligodeoxynucleotide adjuvant.
@ast
Immunoprotective activity and ...... oligodeoxynucleotide adjuvant.
@en
Immunoprotective activity and ...... oligodeoxynucleotide adjuvant.
@nl
prefLabel
Immunoprotective activity and ...... oligodeoxynucleotide adjuvant.
@ast
Immunoprotective activity and ...... oligodeoxynucleotide adjuvant.
@en
Immunoprotective activity and ...... oligodeoxynucleotide adjuvant.
@nl
P2093
P2860
P1433
P1476
Immunoprotective activity and ...... oligodeoxynucleotide adjuvant.
@en
P2093
David D Porter
Dennis M Klinman
Gregory A Prince
James J Mond
Kevin C Yim
Steve J Lan
P2860
P304
13156-13160
P356
10.1128/JVI.77.24.13156-13160.2003
P407
P577
2003-12-01T00:00:00Z